LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
139.58
-1.85 (-1.31%)
At close: 4:06PM EST

139.58 0.00 (0.00%)
Pre-Market: 9:00AM EST

Stock chart is not supported by your current browser
Previous Close141.43
Open140.88
Bid137.61 x 800
Ask141.94 x 900
Day's Range139.36 - 141.74
52 Week Range101.36 - 141.97
Volume5,393,587
Avg. Volume3,500,288
Market Cap134.015B
Beta (5Y Monthly)0.20
PE Ratio (TTM)16.91
EPS (TTM)8.26
Earnings DateJan 29, 2020
Forward Dividend & Yield2.96 (2.12%)
Ex-Dividend DateFeb 11, 2020
1y Target Est133.08
  • Reuters

    Drugmakers slash prices to be eligible for China's bulk-buy program

    Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest bidding round under China's national bulk-buy program, government officials said late on Friday. Beijing has been pushing forward the program where drugmakers have to go through a bidding process and cut prices low enough to be considered over generic copies and be allowed to sell their products at public hospitals via large-volume government procurement. Some global firms such as AstraZeneca and Merck have already cautioned about intensifying price pressures on their mature brands in the world's second largest drug market, as China expands the usage of the program.

  • Benzinga

    9 Takeaways From The JPMorgan Healthcare Conference

    The JPMorgan Healthcare Conference, which showcases innovations in the industry and provides a platform to exchange ideas and insights as well as to make breaking announcements, went by without much fanfare ...

  • Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates
    Zacks

    Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates

    Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.

  • Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction
    Zacks

    Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction

    Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.

  • Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - CFO
    Reuters

    Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - CFO

    Eli Lilly and Co aims to announce roughly one $1 billion (765 million pounds) to $5 billion (3.8 billion pounds) deal every quarter in 2020, its chief financial officer told Reuters, as the U.S. drugmaker looks to build up its pipeline of future products. It will focus largely on earlier stage opportunities across key therapeutic areas including oncology, pain, immunology, and neurology, CFO John Smiley told Reuters in an interview at the JP Morgan Healthcare conference in San Francisco earlier this week. Eli Lilly has been on a deal-making spree in recent years in a bid to increase products and sales in core franchises as older blockbuster medicines, such as diabetes treatment Humalog, face generic competition and pressure to lower prices.

  • Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020: CFO
    Reuters

    Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020: CFO

    Eli Lilly and Co aims to announce roughly one $1 billion to $5 billion deal every quarter in 2020, its chief financial officer told Reuters, as the U.S. drugmaker looks to build up its pipeline of future products. It will focus largely on earlier stage opportunities across key therapeutic areas including oncology, pain, immunology, and neurology, CFO John Smiley told Reuters in an interview at the JP Morgan Healthcare conference in San Francisco earlier this week. Eli Lilly has been on a deal-making spree in recent years in a bid to increase products and sales in core franchises as older blockbuster medicines, such as diabetes treatment Humalog, face generic competition and pressure to lower prices.

  • Eli Lilly (LLY) Gains But Lags Market: What You Should Know
    Zacks

    Eli Lilly (LLY) Gains But Lags Market: What You Should Know

    Eli Lilly (LLY) closed the most recent trading day at $141.43, moving +0.23% from the previous trading session.

  • Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement
    PR Newswire

    Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement

    Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2019 financial results on Thursday, January 30, 2020. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.

  • FDA Risks Sacrificing Its Standards for Speed
    Bloomberg

    FDA Risks Sacrificing Its Standards for Speed

    (Bloomberg Opinion) -- Today’s Food and Drug Administration moves much faster than it used to. That may not always be a good thing. A review of drug approvals by the agency from researchers at Harvard Medical School released Tuesday found that the FDA is approving drugs more rapidly with weaker evidence than it did in the past. That can be beneficial when it leads to needed medicines getting to market quickly, and I believe that’s the agency’s intent. As the study’s authors highlight, however, this emphasis on speed and flexibility could be eroding standards. It may be time for a gut check.The gold standard for demonstrating efficacy — and the surest way of winning drug approval — is to demonstrate success in large, well-controlled studies that result in a hard outcome. But there are faster ways to get to market. In 1992, Congress created the accelerated approval program, which can green light medicines based on “surrogate” endpoints that predict rather than confirm benefit for patients, or those that have shown a shorter-term benefit. It’s one of several initiatives that have changed how the agency works. According to the study, 80.6% of approvals between 1995 and 1997 were supported by at least two pivotal trials. That number dropped to 52.8% between 2005 and 2017. Companies that get accelerated approval have to prove their drug works with a confirmatory trial in order to gain full approval, but there’s no hard timetable no when that must be done. Thus, drugmakers often don't hurry to conduct those tests. This is problematic at best, dangerous at worst.Here’s just one case: In 2016, Sarepta Therapeutics Inc. sought approval of a medicine to treat a rare muscle-wasting disease in young boys based on weak evidence from a tiny trial. In the face of significant public pressure, the FDA approved Exondys 51 even though one of its scientists called the treatment “an elegant placebo” in a report. Sarepta is selling the drug for over $300,000 a year but has continually delayed a confirmatory trial. It’s now years away from completion, and there have been no real consequences for the delay.When companies do complete post-approval trials, it sometimes reveals a mistake. Eli Lilly & Co.’s cancer drug Lartruvo got accelerated approval in 2016. Lilly then pulled the medicine from the market last year after a larger trial found no benefit. That’s a rare outcome, but there are many expensive drugs on the market that have never moved beyond surrogate endpoints. A study of 93 accelerated cancer drug approvals between 1992 and 2017 found that only 19 had proved to help patients live longer in a followup trial. There are some good reasons for faster approvals, as former FDA Commissioner Scott Gottlieb outlined in a Twitter response this week to a critical New York Times editorial penned on Jan. 11. Scientists are better at evaluating the safety of medicines and trial design has improved, for example. And advances have made it easier to create drugs that target small populations and have dramatic effects, Gottlieb wrote.He makes good points. But the agency arguably hasn’t found the right balance between embracing advances and maintaining a high bar. It certainly has a ways to go on post-approval follow up. America is entirely unable to control the price of new medicines; the approval of marginal drugs has financial consequences. The FDA will soon face one of its most important and controversial decisions yet. Biogen Inc. is seeking approval for the first purportedly disease-modifying Alzheimer’s drug — a medicine that could be used by millions of people and cost billions — without good evidence that it works. The agency often uses unmet need as a justification for shifting standards, and there’s no bigger unmet need than Alzheimer’s. That doesn’t justify an approval based on one failed trial and another that is a questionable success at best.The agency will have to decide whether to review or approve the medicine in the next year or so. This choice is an opportunity to resist public pressure and move back toward demanding firmer proof of efficacy before drugs hit the market. To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • J&J Seeks Label Expansion for Spravato Nasal Spray in EU
    Zacks

    J&J Seeks Label Expansion for Spravato Nasal Spray in EU

    J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.

  • Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA
    Zacks

    Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA

    The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.

  • Nektar's Pain Drug Gets Adverse Advisory Committee Decision
    Zacks

    Nektar's Pain Drug Gets Adverse Advisory Committee Decision

    Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.

  • Barrons.com

    Democrats Called for Cuts to Drug Prices at the Debate. The Pharma Industry Says It’s Trying.

    Pharmaceutical executives at the J.P. Morgan Healthcare conference say the industry can fixed pricing problems on its own.

  • Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins
    Zacks

    Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins

    Eli Lilly (LLY) announced plans to launch cheaper version of its Humalog insulins, Mix75/25 KwikPen and Junior KwikPen.

  • Benzinga

    The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 14.) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ...

  • Lilly, Anna Kaiser Launch '30-Day Thriver Challenge' to Increase Awareness of Daily Stress of Living with Metastatic Breast Cancer, Elevate Support for Women and Men Living with the Disease
    PR Newswire

    Lilly, Anna Kaiser Launch '30-Day Thriver Challenge' to Increase Awareness of Daily Stress of Living with Metastatic Breast Cancer, Elevate Support for Women and Men Living with the Disease

    \- An estimated 113 people die every day in the U.S. from metastatic breast cancer (MBC).1 This devastating statistic adds to the emotional and mental weight of living with incurable cancer.

  • Eli Lilly ends deal with NextCure worth up to $1.4B for the local biotech
    American City Business Journals

    Eli Lilly ends deal with NextCure worth up to $1.4B for the local biotech

    Under the deal, inked in November 2018, NextCure gave Eli Lilly access to its proprietary platform for research aimed at developing and commercializing new cancer therapies.

  • Moody's

    Eli Lilly and Company -- Moody's announces completion of a periodic review of ratings of Eli Lilly and Company

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Eli Lilly and Company and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • Barrons.com

    Big Merger Deals Are Missing at Health Conference. Here’s Why.

    What a difference a year makes. The start of the annual J.P. Morgan Healthcare investor conference in 2019 brought a double-header of giant deals. In 2020, there was almost nothing.

  • Benzinga

    The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter International ...

  • MarketWatch

    Eli Lilly to make two more cheaper insulin products available from mid-April

    Eli Lilly and Co. said Tuesday it is planning to add two more cheaper versions of its insulin product Humalog starting in mid-April. The drug company said its Humalog Mix75/25 KwikPen and Humalog Junior KwikPen will have list prices that are 50% lower than branded versions. The company first made a version of its lower-priced Insulin Lispro Injection available in May of last year at a 50% lower list price than Humlalog. More than 67,000 people filled prescriptions for that product in November of 2019 and another roughly 10% of people using Humalog transitioned to the lower-priced product. Lilly shares have gained 21% in the last 12 months, while the S&P 500 has gained 27%.

  • Lilly expands insulin affordability options with lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen®
    PR Newswire

    Lilly expands insulin affordability options with lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen®

    Eli Lilly and Company (NYSE: LLY) today announced plans to add two more cost-saving options to its suite of solutions for people who use Lilly insulin by introducing lower-priced versions of Humalog® Mix75/25™ KwikPen® (insulin lispro protamine and insulin lispro injectable suspension 100 units/mL) and Humalog® Junior KwikPen® (insulin lispro injection 100 units/mL). Both insulins will have 50 percent lower list prices compared to the branded versions and will be available by mid-April.

  • ACCESSWIRE

    SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Dermira, Inc. - (Nasdaq:DERM)

    BALA CYNWYD, PA / ACCESSWIRE / January 13, 2020 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Dermira, Inc. ("Dermira" ...

  • ACCESSWIRE

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Dermira, Inc. to Eli Lilly and Company is Fair to Shareholders

    NEW YORK, NY / ACCESSWIRE / January 13, 2020 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Dermira, Inc. ("Dermira" or the "Company") ...

  • Eli Lilly Interested in Bolt-On Acquisitions, CEO Says
    Bloomberg

    Eli Lilly Interested in Bolt-On Acquisitions, CEO Says

    Jan.14 -- Dave Ricks, Eli Lilly & Co. chief executive officer, discusses the company's product pipeline and acquisition strategy with Bloomberg's Taylor Riggs at the JPMorgan Health Care Conference in San Francisco on "Bloomberg Markets."